Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Botox Gets UK Approval for Migraine | Contract Pharma

What are you searching for?

Sign in

Botox Gets UK Approval for Migraine

Allergan’s Botox has been licensed by the MHRA in the UK for the prevention of headaches in adults who have chronic migraine (headaches on at least 15 days per month of which at least eight days are with migraine).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Allergan’s Botox has been licensed by the MHRA in the UK for the prevention of headaches in adults who have chronic migraine (headaches on at least 15 days per month of which at least eight days are with migraine). This is the first license of Botox for this indication, and is also the first preventative treatment to receive a specific license for patients with chronic migraine.

“There is an unmet need for effective and well-tolerated therapies specifically designed and studied for the prophylaxis of headache in chronic migraine,” said Scott Whitcup, M.D., Allergan’s executive vice president, R&D and chief scientific officer. “The authorization of Botox marks an evolution in medical care for the prevention of headache in adults with chronic migraine. It is also a significant milestone in the history of Botox and Allergan is proud to advance novel treatments in the field of neurology through our neurosciences research program.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters